Announced Tue, 17 Mar · 13:07 IST

SUBMISSION OF DISCLOSURE UNDER REGULATION 7(2)

Promoter Stake BuyOwnership Changes View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-3.3%1-day move

₹20.69

prior close

₹19.22

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.0+4.0+4.0+4.0-3.3+1.4+3.4-0.9+1.5-11.1+17.5+23.1-2.9+8.6

Up moveDown movePending

AI summary

Beryl Drugs Ltd has submitted a disclosure to BSE under SEBI's Prohibition of Insider Trading Regulations, 2015 (Regulation 7(2)). The disclosure was made by Sudhir Sethi, the main Promoter and Director of the company (DIN: 00090172), reporting his acquisition of 5,000 equity shares. This acquisition represents 0.09% of the company's total share capital. The filing is a routine compliance disclosure by the promoter regarding a small open-market purchase, with no other corporate action indicated.

Likely market impact

The purchase is very small (0.09%) and unlikely to materially affect the stock price, but it signals continued promoter confidence in the company. Retail investors should note that insiders have bought shares, though the size is too small to be a strong market-moving signal.